These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 9099204

  • 1. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs.
    Mousa SA, Mu DX, Lucchesi BR.
    Stroke; 1997 Apr; 28(4):830-5; discussion 835-6. PubMed ID: 9099204
    [Abstract] [Full Text] [Related]

  • 2. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA, DeGrado WF, Mu DX, Kapil RP, Lucchesi BR, Reilly TM.
    Circulation; 1996 Feb 01; 93(3):537-43. PubMed ID: 8565173
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA, Forsythe MS, Diemer M, Bozarth JM, Reilly TM.
    Coron Artery Dis; 1994 Nov 01; 5(11):919-27. PubMed ID: 7719524
    [Abstract] [Full Text] [Related]

  • 7. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
    Lucchessi BR, Rote WE, Driscoll EM, Mu DX.
    Br J Pharmacol; 1994 Dec 01; 113(4):1333-43. PubMed ID: 7889289
    [Abstract] [Full Text] [Related]

  • 8. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J, Rebello SS, Faul JD, Lucchesi BR.
    Pharmacology; 1999 May 01; 58(5):252-64. PubMed ID: 10087466
    [Abstract] [Full Text] [Related]

  • 9. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
    Pedicord DL, Thomas BE, Mousa SA, Dicker IB.
    Thromb Res; 1998 Jun 15; 90(6):247-58. PubMed ID: 9700855
    [Abstract] [Full Text] [Related]

  • 10. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.
    Rote WE, Werns SW, Davis JH, Feigen LP, Kilgore KS, Lucchesi BR.
    Cardiovasc Res; 1993 Mar 15; 27(3):500-7. PubMed ID: 8490951
    [Abstract] [Full Text] [Related]

  • 11. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis.
    Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Apr 15; 23(4):681-9. PubMed ID: 7516023
    [Abstract] [Full Text] [Related]

  • 12. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
    Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nichols AJ, Ohlstein EH.
    Stroke; 1992 May 15; 23(5):703-11. PubMed ID: 1605806
    [Abstract] [Full Text] [Related]

  • 13. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
    Mousa SA, Forsythe M, Wityak J, Bozarth J, Mu DX.
    J Cardiovasc Pharmacol; 1998 Mar 15; 31(3):441-8. PubMed ID: 9514190
    [Abstract] [Full Text] [Related]

  • 14. Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755.
    Mousa SA, Mu DX, Hussain MA.
    Thromb Res; 1998 Nov 01; 92(3):115-24. PubMed ID: 9806363
    [Abstract] [Full Text] [Related]

  • 15. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.
    J Cardiovasc Pharmacol; 1997 Aug 01; 30(2):261-72. PubMed ID: 9269956
    [Abstract] [Full Text] [Related]

  • 16. Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA, Bozarth JM, Forsythe MS, Lorelli W, Thoolen MJ, Ramachandran N, Jackson S, De Grado W, Reilly TM.
    Cardiology; 1993 Aug 01; 83(5-6):374-82. PubMed ID: 7509257
    [Abstract] [Full Text] [Related]

  • 17. Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
    Mousa SA, Bozarth JM, Edwards S, Carroll T, Barrett J.
    Coron Artery Dis; 1998 Aug 01; 9(2-3):131-41. PubMed ID: 9647415
    [Abstract] [Full Text] [Related]

  • 18. Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796.
    Hennan JK, Willens DE, Driscoll EM, Hong TT, Giboulot T, Lucchesi BR.
    J Cardiovasc Pharmacol; 2003 Jul 01; 42(1):71-7. PubMed ID: 12827029
    [Abstract] [Full Text] [Related]

  • 19. Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.
    Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR.
    Br J Pharmacol; 2002 Jul 01; 136(6):927-37. PubMed ID: 12110617
    [Abstract] [Full Text] [Related]

  • 20. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ.
    J Pharmacol Exp Ther; 1997 May 01; 281(2):677-89. PubMed ID: 9152373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.